IL131131A0 - Synthetic hiv gag genes - Google Patents
Synthetic hiv gag genesInfo
- Publication number
- IL131131A0 IL131131A0 IL13113198A IL13113198A IL131131A0 IL 131131 A0 IL131131 A0 IL 131131A0 IL 13113198 A IL13113198 A IL 13113198A IL 13113198 A IL13113198 A IL 13113198A IL 131131 A0 IL131131 A0 IL 131131A0
- Authority
- IL
- Israel
- Prior art keywords
- hiv gag
- synthetic
- synthetic hiv
- gag genes
- codons
- Prior art date
Links
- 108700004026 gag Genes Proteins 0.000 title 1
- 108020004705 Codon Proteins 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3785497P | 1997-02-07 | 1997-02-07 | |
GBGB9705040.5A GB9705040D0 (en) | 1997-03-12 | 1997-03-12 | Synthetic HIV GAG genes |
PCT/US1998/002293 WO1998034640A2 (en) | 1997-02-07 | 1998-02-03 | Synthetic hiv gag genes |
Publications (1)
Publication Number | Publication Date |
---|---|
IL131131A0 true IL131131A0 (en) | 2001-01-28 |
Family
ID=26311165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13113198A IL131131A0 (en) | 1997-02-07 | 1998-02-03 | Synthetic hiv gag genes |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0969862B1 (de) |
JP (1) | JP2001512308A (de) |
KR (1) | KR20000070865A (de) |
CN (1) | CN1252075A (de) |
AT (1) | ATE342916T1 (de) |
AU (1) | AU743616B2 (de) |
CA (1) | CA2280195A1 (de) |
DE (1) | DE69836206T2 (de) |
DK (1) | DK0969862T3 (de) |
EE (1) | EE9900343A (de) |
ES (1) | ES2274566T3 (de) |
IL (1) | IL131131A0 (de) |
NO (1) | NO993810L (de) |
PL (1) | PL335050A1 (de) |
SK (1) | SK106699A3 (de) |
WO (1) | WO1998034640A2 (de) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228128B1 (en) | 1997-11-10 | 2001-05-08 | Charlotte Johansen | Antimicrobial activity of laccases |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
JP2003523721A (ja) * | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
CA2360347C (en) * | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
WO2000029561A2 (en) * | 1999-03-29 | 2000-05-25 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
HUP0201019A2 (en) * | 1999-04-26 | 2002-08-28 | Leuven K U Res & Dev | Synthetic gene for expressing active retroviral protein in eukaryotes |
WO2001002607A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
CA2381991A1 (en) * | 1999-08-25 | 2001-03-01 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
EP1228237A1 (de) | 1999-11-01 | 2002-08-07 | Chiron Corporation | Expressionsvektoren, transfektionssysteme, und verfahren zur verwendung |
US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
US7655774B2 (en) * | 2000-02-18 | 2010-02-02 | University Of Washington | Ancestral and COT viral sequences, proteins and immunogenic compositions |
ATE318908T1 (de) * | 2000-05-18 | 2006-03-15 | Geneart Gmbh | Synthetische gene für gagpol und deren verwendungen |
GB0014288D0 (en) | 2000-06-10 | 2000-08-02 | Smithkline Beecham Biolog | Vaccine |
ATE346947T1 (de) * | 2000-07-21 | 2006-12-15 | Glaxo Group Ltd | Kodon-optimierte papillomavirussequenzen |
WO2002013855A2 (en) | 2000-08-17 | 2002-02-21 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6858590B2 (en) | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
DE50214200D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
CA2450732A1 (en) | 2001-06-14 | 2002-12-27 | John H. Griffin | Stabilized proteins with engineered disulfide bonds |
CA2634992C (en) | 2001-07-05 | 2012-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
EP1409694A4 (de) | 2001-07-05 | 2006-02-08 | Chiron Corp | Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen |
WO2003012117A1 (en) * | 2001-07-28 | 2003-02-13 | The Secretary Of State For Defence | Dna vaccine |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
FR2845918A1 (fr) * | 2002-10-16 | 2004-04-23 | Pasteur Institut | Preparations immunogenes et vaccinantes a base d'arn |
AU2003235707A1 (en) * | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
DE10260805A1 (de) * | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
US7276243B2 (en) | 2003-03-24 | 2007-10-02 | Merck & Co., Inc. | Optimized expression of HPV31 L1 in yeast |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
GB0321614D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Vaccines |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
ATE554106T1 (de) | 2003-12-23 | 2012-05-15 | Arbor Vita Corp | Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung |
CN1934131B (zh) | 2004-03-24 | 2010-12-29 | 默沙东公司 | Hpv52l1在酵母中的优化表达 |
DE102004037611B4 (de) | 2004-08-03 | 2013-10-02 | Geneart Ag | Induzierbare Genexpression |
CA2585672A1 (en) | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
KR101158756B1 (ko) | 2006-12-20 | 2012-06-22 | (주) 에빅스젠 | 코돈 최적화시킨 hiv의 nc 폴리뉴클레오티드, 상기폴리뉴클레오티드를 포함하는 벡터 및 이를 이용한 nc단백질의 생산방법 |
EP2185195A2 (de) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen-plattform |
JP2011506334A (ja) | 2007-12-07 | 2011-03-03 | ノバルティス アーゲー | 免疫応答を誘導するための組成物 |
AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
WO2011094259A2 (en) | 2010-01-28 | 2011-08-04 | Glaxo Group Limited | Cd127 binding proteins |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
CA2805035A1 (en) | 2010-07-22 | 2012-01-26 | Glaxosmithkline Biologicals S.A. | Novel antigen binding proteins |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
WO2013166099A1 (en) | 2012-05-01 | 2013-11-07 | Glaxosmithkline Llc | Novel antibodies |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP129A (en) * | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5480967A (en) * | 1990-01-05 | 1996-01-02 | United Biomedical, Inc. | HIV-1 core protein fragments |
CA2118026A1 (en) * | 1992-04-14 | 1993-10-28 | Guy T. Layton | Induction of ctl responses |
AU675702B2 (en) * | 1993-01-26 | 1997-02-13 | Leslie R. Coney | Compositions and methods for delivery of genetic material |
US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AU729231B2 (en) * | 1996-02-22 | 2001-01-25 | Merck & Co., Inc. | Synthetic HIV genes |
US6114148C1 (en) * | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
-
1998
- 1998-02-03 JP JP53490598A patent/JP2001512308A/ja active Pending
- 1998-02-03 EP EP98904971A patent/EP0969862B1/de not_active Expired - Lifetime
- 1998-02-03 DE DE69836206T patent/DE69836206T2/de not_active Expired - Fee Related
- 1998-02-03 CN CN98803975A patent/CN1252075A/zh active Pending
- 1998-02-03 WO PCT/US1998/002293 patent/WO1998034640A2/en active IP Right Grant
- 1998-02-03 EE EEP199900343A patent/EE9900343A/xx unknown
- 1998-02-03 AU AU62711/98A patent/AU743616B2/en not_active Ceased
- 1998-02-03 IL IL13113198A patent/IL131131A0/xx unknown
- 1998-02-03 SK SK1066-99A patent/SK106699A3/sk unknown
- 1998-02-03 ES ES98904971T patent/ES2274566T3/es not_active Expired - Lifetime
- 1998-02-03 AT AT98904971T patent/ATE342916T1/de not_active IP Right Cessation
- 1998-02-03 PL PL98335050A patent/PL335050A1/xx unknown
- 1998-02-03 DK DK98904971T patent/DK0969862T3/da active
- 1998-02-03 CA CA002280195A patent/CA2280195A1/en not_active Abandoned
- 1998-02-03 KR KR1019997007130A patent/KR20000070865A/ko not_active Application Discontinuation
-
1999
- 1999-08-06 NO NO993810A patent/NO993810L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1998034640A2 (en) | 1998-08-13 |
NO993810D0 (no) | 1999-08-06 |
CN1252075A (zh) | 2000-05-03 |
WO1998034640A3 (en) | 1998-11-19 |
EP0969862A2 (de) | 2000-01-12 |
DK0969862T3 (da) | 2007-02-12 |
ATE342916T1 (de) | 2006-11-15 |
JP2001512308A (ja) | 2001-08-21 |
AU6271198A (en) | 1998-08-26 |
KR20000070865A (ko) | 2000-11-25 |
SK106699A3 (en) | 2000-06-12 |
EE9900343A (et) | 2000-02-15 |
DE69836206T2 (de) | 2007-08-23 |
NO993810L (no) | 1999-10-07 |
ES2274566T3 (es) | 2007-05-16 |
DE69836206D1 (de) | 2006-11-30 |
AU743616B2 (en) | 2002-01-31 |
PL335050A1 (en) | 2000-03-27 |
CA2280195A1 (en) | 1998-08-13 |
EP0969862B1 (de) | 2006-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL131131A0 (en) | Synthetic hiv gag genes | |
NZ331161A (en) | Synthetic HIV genes encoding envelope (env) proteins | |
PT1212358E (pt) | Genes sinteticos de papilomavirus humano | |
MX9700229A (es) | Vacuna de polinucleotido para virus de papiloma. | |
TR200001835T2 (tr) | Aşı. | |
EP0789593A4 (de) | Auf hefe basierte vehikel zur abgabe | |
EP0256092A4 (de) | Abgeschwächte herpesviren, herpesviren, die eine für aminosäuresequenzen kodierende fremd-dns enthalten, sowie impfstoffe, die diese enthalten. | |
WO2003059381A3 (en) | Immunogenic preparations and vaccines on the basis of mrna | |
AU7690898A (en) | Vectors and methods for immunization or therapeutic protocols | |
HK1153761A1 (en) | Cancer antigens based on products of the tumor suppressor gene wt1 wt1 | |
AU1013601A (en) | Method of inducing and/or enhancing an immune response to tumor antigens | |
WO2002032943A3 (en) | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization | |
GB9722682D0 (en) | Pharmaceutical products | |
ATE285239T1 (de) | Dna enthaltende impfstoffen | |
AU4088697A (en) | Postinfection human immunodeficiency virus (hiv) vaccination therapy | |
HK1082666A1 (en) | Ihnv g fusion protein for immune stimulation | |
NZ213249A (en) | Protein antigen, dna, plasmid, transformed microorganism and influenza vaccine | |
ATE346087T1 (de) | Hepatitis e-virus aus dem schwein und dessen verwendungen | |
ECSP972034A (es) | Genes sinteticos vih | |
EA199900726A1 (ru) | Синтетические hiv gag гены | |
EA199800750A1 (ru) | Синтетические гены вич | |
PT980379E (pt) | Oligonucleotidos quimericos e sua utilizacao | |
WO1999061049A3 (en) | Model for infection by a pathogen using administration of nucleic acids | |
WO2002070554A3 (en) | Dna encoding human cid2 | |
FR2730936B1 (fr) | Vaccin presentant une immunogenicite accrue |